This HTML5 document contains 189 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1586/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q54214722
rdf:type
wikibase:Item
schema:description
2016年学术文章 2016년 논문 bài báo khoa học 2016年学术文章 vedecký článok مقالهٔ علمی naučni članak 2016年學術文章 teaduslik artikkel научни чланак 2016年學術文章 tieteellinen artikkeli vědecký článek artículo científico publicado en 2016 სამეცნიერო სტატია bilimsel makale vitenskapelig artikkel artikull shkencor מאמר מדעי article scientific 2016年學術文章 artículu científicu επιστημονικό άρθρο ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ vitskapeleg artikkel artigo científico 2016 nî lūn-bûn article científic tudományos cikk 2016年の論文 2016年學術文章 vetenskaplig artikel سائنسی مضمون scienca artikolo scientific article научна статия 2016年学术文章 mokslinis straipsnis article scientifique (publié 2016) videnskabelig artikel (udgivet 2016) articol științific 2016年学术文章 научни чланак 2016年學術文章 artikulong pang-agham wetenschappelijk artikel мақолаи илмӣ գիտական հոդված мақолаи илмӣ 2016年学术文章 наукова стаття, опублікована в лютому 2016 2016年學術文章 artigo científico (publicado na 2016) wissenschaftlicher Artikel articolo scientifico artykuł naukowy artigo científico (publicado na 2016) บทความทางวิทยาศาสตร์ научная статья مقالة علمية
p:P577
wds:Q54214722-742F2B6B-685C-4082-A938-C8456F3E92C8
wdt:P577
2016-02-16T00:00:00Z
p:P407
wds:Q54214722-E7B36339-EC82-46A0-B3D5-712A547B63B2
wdt:P407
wd:Q1860
p:P2860
wds:Q54214722-01D6E81B-1933-42AE-BB15-5D86D1BBB7E0 wds:Q54214722-3E5F8D52-DBF1-44C8-9FDB-C0C86C457718 wds:Q54214722-3FEE4446-CA83-4B4B-81AD-F8C153C2532B wds:Q54214722-429405F5-9C78-4136-B677-3A10E1D4958C wds:Q54214722-54E7A041-D184-4A47-8A0E-919E96ECD000 wds:Q54214722-055F3194-7157-4188-B89A-50C47BC1C099 wds:Q54214722-0F1F31CE-3AE9-42B5-8E15-CADDC695162B wds:Q54214722-1578227A-3D9B-4CA0-AF55-6BBCF1BD9502 wds:Q54214722-19347155-B879-4E9F-BC31-563E8C875D5E wds:Q54214722-27AEAB26-E285-44EF-B7EC-67186ACCE231 wds:Q54214722-2FCD71E2-FAF5-481D-8EDF-D28233EB437D wds:Q54214722-361D7C5C-FC71-477D-9789-6C28386229C5 wds:Q54214722-7E6EC920-1845-4AFD-9807-888CAC91C8B1 wds:Q54214722-7EE5DCB9-ACBE-4662-96EE-82FA10F80322 wds:Q54214722-81D27D18-A47D-4161-8FB0-915913B8096E wds:Q54214722-87BE1939-836A-4EB6-9183-F5F9C8FEB3A6 wds:Q54214722-98E9FFD2-1F58-4283-876E-12DB3640EFE8 wds:Q54214722-9FDCDB45-FACA-4DEB-9D26-A5648B99D460 wds:Q54214722-A070C8F3-7A56-44B9-8F1D-079ED2A67C9E wds:Q54214722-5808009C-0ECD-4122-A8F9-095634F5209C wds:Q54214722-6A88EDA5-AF3C-40B5-BDFA-0A47A4938554 wds:Q54214722-6BD178F4-2AFC-468F-979B-6C1C878EB29A wds:Q54214722-6EE0F5BD-F026-415A-A974-1D9E06EC5D21 wds:Q54214722-7217043D-2BB2-405E-838C-E088090E0E27 wds:Q54214722-B18DD21E-58A0-4188-B930-18E505855857 wds:Q54214722-B395C570-6AAB-4FD8-99DB-5EF14B9D636D wds:Q54214722-B93AF079-2238-4AB4-85A4-9F69E7A88F6A wds:Q54214722-BB34423C-5A55-4C95-830D-FE7DF7C0F0EF wds:Q54214722-BC489092-5A05-4C7D-B732-9AFACBB1D4E8 wds:Q54214722-C08FA548-2E50-4ED8-BB43-6DBAC697950A wds:Q54214722-C20474D6-905E-453A-9C0D-E3BD1004C74A wds:Q54214722-A33EAF9C-9671-4F76-B3FE-9D13A995AEB9 wds:Q54214722-A373750D-26ED-4CD2-9939-F9E59A0E2B81 wds:Q54214722-A757C25A-10B5-45E4-AED8-C494210F64B1 wds:Q54214722-A8A7D08B-EF13-476F-ADE2-15CF2DDB43B7 wds:Q54214722-AACEF852-EA71-43ED-AD37-F55275EB31C7 wds:Q54214722-AC1A3F11-0C6A-44E5-9438-DB957C67707A wds:Q54214722-AE767C01-0625-455C-A362-38D26A3523B7 wds:Q54214722-B1549470-5259-4614-85A8-82D3E1E0E48C wds:Q54214722-E731A875-B894-4A85-8FFF-D059193E0B82 wds:Q54214722-F52B8F37-511A-41EA-9B35-385A6DACD9EB wds:Q54214722-C28BB0B3-3C4B-46AC-BD46-A0D4331D971F wds:Q54214722-C7B46CCC-E586-44BF-A9F6-987CA8786A28 wds:Q54214722-CD5F0532-A71A-4199-B6AF-C580AA4E6D5F wds:Q54214722-D454A253-1F98-4FBE-AA36-542BCBE9F03A wds:Q54214722-D464972B-8CC8-4ACF-BF79-1E41AE9B10F4 wds:Q54214722-D54A9C81-A5C9-45C3-B402-5E24689D2DBC wds:Q54214722-D78D21F1-C25F-4F7A-B129-ECB745D663F2 wds:Q54214722-E419E977-9C09-4DE4-8399-99395A8E8298
wdt:P2860
wd:Q39435771 wd:Q52970666 wd:Q38309808 wd:Q34483765 wd:Q36368478 wd:Q38623447 wd:Q35620368 wd:Q34658294 wd:Q48069153 wd:Q48282794 wd:Q37506748 wd:Q34169114 wd:Q34482156 wd:Q42705157 wd:Q46272550 wd:Q46903707 wd:Q34486040 wd:Q54381972 wd:Q41893567 wd:Q38284197 wd:Q26775111 wd:Q41230071 wd:Q34479570 wd:Q27009742 wd:Q43720865 wd:Q26800937 wd:Q38349779 wd:Q38211580 wd:Q48059175 wd:Q38656130 wd:Q37926574 wd:Q48322904 wd:Q34084020 wd:Q38317993 wd:Q38229893 wd:Q38285771 wd:Q36475599 wd:Q54487976 wd:Q46191430 wd:Q38561061 wd:Q26778531 wd:Q26771682 wd:Q27001957 wd:Q53255833 wd:Q34771528 wd:Q35935340 wd:Q48005178 wd:Q36299948 wd:Q35740706
p:P2093
wds:Q54214722-79A761DD-EA7F-4CA8-9BCB-165142262FD2 wds:Q54214722-4A78060A-9236-4039-BF20-24A483DC0FC2 wds:Q54214722-39671EA1-742A-4CF5-BBC5-3146454BA653 wds:Q54214722-0F1098F6-5A0D-4849-8F00-C9C17106E52A
wdt:P2093
Ali Alikhan Dane Hill Abraham M Korman Steven R Feldman
rdfs:label
Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis. Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis.
skos:prefLabel
Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis. Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis.
schema:name
Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis. Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis.
p:P1476
wds:Q54214722-5221C8C8-381C-4B1B-A204-01EC4C419333
wdt:P1476
Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis.
p:P31
wds:Q54214722-580602B8-2CC3-4731-BD15-4DC2FE503787
wdt:P31
wd:Q13442814
p:P698
wds:Q54214722-5097238A-0129-4C7C-8D30-F6AAB404C8CB
wdtn:P698
n9:26881913
wdt:P698
26881913
p:P1433
wds:Q54214722-68A4BB2E-9F2A-49CE-8822-566DCBB64169
wdt:P1433
wd:Q15793519
p:P356
wds:Q54214722-B8D7E304-34A3-4DB7-9AF4-1CD40FABB5FD
wdtn:P356
n12:17512433.2016.1154785
wdt:P356
10.1586/17512433.2016.1154785